Bevacizumab has been shown in vivo to decrease expression of profibrogenic genes TGFB and ACTA2, as well as decreasing overall HSC activation, altogether attenuating hepatic fibrosis in a CCl4-rat model (Huang et al., 2013). Here, TGFB1 is linked to Hepatic fibrosis.